NFKB1 and autoimmune hepatitis: Concanavalin A induces autoimmune hepatitis with significantly increased hepatic expression of TNF-α, IL-6, IL-1, HMGB1 and NF-kB activation, EP treatment (1 h before the Con A injection, a single dose of EP was intraperitoneally injected to the animals in the 40 mg/kg EP group and the 80 mg/kg EP group; liver tissue samples were obtained 3 h, 6 h and 24 h after Con A injection) reduces all of these changes and resultantly ameliorates Concanavalin induced autoimmune hepatitis [44], which can be fatal.